Stories With VisionU of A Scientists First to Pinpoint a Cause of Pigmentary GlaucomaPosted on: Feb 01, 2019
Discovery identifies gene that causes common form of blindness worldwide, potentially leading to new treatment for glaucoma.
By Ross Neitz. Reposted with permission from the University of Alberta Faculty of Medicine and Dentistry website.
“We are confident that the Alberta Vision Net model of coordinated vision science research across the province will lead to advances in the care of patients.”
Andrew Otway, President and CEO of the Royal Alexandra Hospital Foundation
An international team of researchers has identified a gene responsible for the onset of pigmentary glaucoma. It is the first time ever a cause of the disease has been identified and may lead to new therapies for the condition in the future.
“People who traditionally we wouldn't think of having glaucoma—young males in their 20s and 30s—are at particular risk for this form of the disease and of losing their vision,” said Michael Walter, professor and chair of Medical Genetics at the University of Alberta. “The impact of pigmentary glaucoma for these individuals is very dire, so we need to be able to develop better therapies for them.”
Pigmentary glaucoma (PG) occurs when the pigment on the back of the iris gets deposited into the front part of the eye, causing vision loss and eventually blindness if left untreated. It’s estimated that at least 150,000 people in North America are affected by the condition.
The study, led by Walter, also involved researchers at Harvard University and Flinders University in Australia. The team, using data from two individual families with a predisposition toward PG, used a technique known as whole exome sequencing to identify the premelanosome protein (PMEL) gene as a gene associated with pigmentary glaucoma. The finding was further confirmed through detection of more PMEL gene mutations following examination of 400 additional patient samples.
The researchers determined that the mutations in the PMEL gene had biological consequences, using a series of biochemical and cell biology tests to show that most of the mutations significantly altered human cells. Collaborating with Ted Allison, an associate professor of biological sciences in the Faculty of Science, the team used gene-editing technology called CRISPR Cas9 to introduce the mutations into the DNA of zebrafish.
“We found that these fish had altered pigmentation and eye defects which were very reminiscent of human glaucoma,” said Walter. “Altogether, the findings showed us quite clearly that we have identified a new gene that causes glaucoma.”
“I think the collaborative effort we’ve had in this research has really let us explore this more fully than any one lab could have done.”
Walter, who is also a member of Alberta Vision Net which brings together researchers from the University of Alberta and University of Calgary to advance the understanding and treatment of ocular disease, is now focused on efforts to better understand how the mutations lead to pigmentary glaucoma. He says the research has also identified unexpected similarities to other neurodegenerative diseases, such as Alzheimer’s, that could lead to exciting new possibilities for treatment.
“It opens up awareness about other approaches we could take,” said Walter. “Potentially some of the methods that are currently being used to think about treating Alzheimer’s might even be applied to treat glaucoma.”
“We are confident that the Alberta Vision Net model of coordinated vision science research across the province will lead to advances in the care of patients,” said Andrew Otway, president and CEO of the Royal Alexandra Hospital Foundation, a major funder of the research.
The research, which was published in Human Molecular Genetics, was also supported by funding from the Canadian Glaucoma Research Society, Alberta Vision Network, Canadian Institutes of Health Research, Maternal and Child Health Student Support, the BrightFocus Foundation, March of Dimes Foundation, and the National Institutes of Health.